PIK3CA N345K

CI-VAR-00002900Explore in graph →NP_006209.2:p.Asn345LysNM_006218.3:c.1035T>AClinVar 376050 CIViC 930 rs121913284

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
PIK3CA N345K OR PIK3CA N345D OR PIK3CA N345H OR PIK3CA N345I OR PIK3CA N345S OR PIK3CA N345T OR PIK3CA N345Y	Fulvestrant + Inavolisib + PalbociclibCombination	Predictive	A	Supports Sensitivity Response	3	accepted	EID12538 The phase III INAVO120 trial (NCT04191499) in 325 patients with endocrine-resistant, PIK3CA-mutated HR⁺/HER2⁻ locally advanced or metastatic breast cancer evaluated inavolisib plus palbociclib and ful… (full text at CIViC) PMID 40845250 · Wedam et al., 2025 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
PIK3CA N345K	Cetuximab	Predictive	C	Supports Resistance	1	accepted	EID4047

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376050	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Abnormal cardiovascular system morphology; PIK3CA related overgrowth syndrome; Neoplasm; Rosette-forming glioneuronal tumor; Diffuse midline glioma, H3 K27M-mutant	germline/somatic	6	Oct 27, 2023	clinvar

Squamous Cell Carcinoma1
PIK3CA N345K OR PIK3CA M1043V OR PIK3CA Q75E	Alpelisib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12160 In this pre-clinical study, the role of the non-canonical PIK3CA mutation PIK3CA Q75E was evaluated. The expression of pKAT/total AKT was compared across canonical PIK3CA E545K mutation, non-canonical… (full text at CIViC) PMID 34779417 · Jin et al., 2021 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease
PIK3CA N345K	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	3	submitted	EID12182 In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic